However, it still remains to be addressed what tumor-specific genetic or epigenetic changes lead to unresponsiveness in TAb2 or sensitize TCh3 to anti-PD-L1 treatment, and whether such changes are also applicable to the heterogeneous ICI responses in human HNSCCs. This evidence concerns the gene CD274 and neoplasm.